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ABSTRACT

Pharmacokinetics involves the analysis of plasma concentration and time data to obtain
models that summarize the absorption , distribution and elimination parameters of a
drug. The population approach to pharmacokinetics involves the estimation of mean
pharmacokinetic parameters and their variability within the population.

Cyclosporine is a widely used immunosuppressive agent, and its pharmacokinetic
parameters are characterized by a large variation in blood concentrations after oral or
intravenous administration. Cyclosporine being a narrow therapeutic index drug is
associated with significant consequences if the drug is present in 'sub-therapeutic' or
'supra-therapeutic' concentration. Optimization of therapy is challenging owing to
variable pharmacokinetic parameters and narrow therapeutic index.

(
Population pharmacokinetic approach is used in this study to identify and characterize
demographic and pharmacological variables that influence the pharmacokinetics of
cyclosporine in lung transplant recipients.

Cyclosporine concentration-time data obtained through a randomized, prospective
clinical trial was re-analyzed. A total of 1004 abbreviated cyclosporine profiles were
available from 48 patients at 1, 2, 3, 4, 12, 24, 36 and 52 post operative weeks.
Population modeling was performed using NONMEM (Version V). A onecompartment model with first-order absorption and elimination was used to model the
data. Exponential models were used for inter-individual variation on oral clearance

(CUF) and volume of distribution (V!F). A proportional model was used for
residual error.

Estimates of CUF and V!F (±S.E) were 26.4 (3 .7) Uh and 183 (37) L,
respectively. Concomitant itraconazole and diagnosis of cystic fibrosis were
identified as significant covariates for CUF. Time post transplant and different
formulations were significant when modeled on bioavailability. With this model
the estimated coefficients of variation were 18.5% and 49.6% for interpatient
variability in CUF and residual variability, respectively. Patients taking
itraconazole were found to have a CUF of 11.6 (4.3) Uh, 43.9% that of the other
patients. Patients with cystic fibrosis had CUF of 52.3 (6.9) Uh, 50% higher
than patients without cystic fibrosis . Relative bioavailability of cyclosporine
from Sandimmune® was 87% that of Neoral®.

In conclusion, the covariates which influenced the pharmacokinetics of study
population were concomitant itraconazole, diagnosis of cystic fibrosis, time post
transplant and different formulation.
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PREFACE

This document was prepared in the format of manuscript plan in accordance to the
Graduate School guidelines of the University of Rhode Island. The thesis is divided
into two sections.

Section I is composed of two manuscripts. Manuscript I is a general introduction to the
topic of research, encompassing the introduction to pharmacokinetics, population
pharmacokinetics, cyclosporine and cystic fibrosis. Manuscript II consists of the main
body of this thesis, written in a format required for scientific journal submission.
Section II contains appendix that includes additional information and details of control
file useful in the analysis to understand the work in Section I. A bibliography follows
section II in which all sources used as references in this document are cited.
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MANUSCRIPT I

INTRODUCTION

Pharmacokinetics is the study of the relationship between the dose of a drug
and the manner in which its plasma concentrations change over time. More
specifically, pharmacokinetics involves the analysis of plasma concentration
and time data to obtain models that summarize the dose-plasma concentration
relationship in terms of the absorption, distribution and elimination parameters
of a drug. An understanding of drug's pharmacokinetic characteristics is
important for drug development and the determination of safe and effective
doses. Pharmacokinetic studies can also be used to investigate the effects of
demographical characteristics such as weight, disease status, sex, age etc that
may influence the dose-plasma concentration profile (1).

There are broadly two ways of determining a drug's pharmacokinetic
characteristics in a population. Firstly, the traditional analysis which involves
modeling each individual's concentration-time data to obtain individual
pharmacokinetic parameters. Individual parameters are then averaged to
determine the population values. Secondly pharmacokinetic analysis can also
be conducted using a population approach in which the pharmacokinetic
parameters of the population are determined directly.

1
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The traditional approach to pharmacokinetic studies involves taking intensive
plasma samples, up to 10-20 per individual, from a small group of subjects or
patients. The data from

each subject are individually fitted

to a

pharmacokinetic model (e.g., a one- or two- compartment model) to obtain the
individual's pharmacokinetic parameters. Then summary statistics such as the
mean and the variance of the group are calculated by pooling each individual's
pharmacokinetic parameters. Limitations to the traditional approach are that
only a small number of individuals can be studied and the subjects tend to be
either healthy volunteers or relatively healthy patients with only a mild form of
the disease. Thus the population is generally not representative of the true
population to be treated (2).

In contrast to the traditional approach, the population approach to
pharmacokinetic modeling often uses sparse data i.e. only a few samples from
each subject. The sparse sampling is balanced with study of a large and often
diverse study population. The population approach also provides estimates of
the inter-individual variability of the pharmacokinetic parameters in the
population. Sources of inter-individual variability such as patient age, weight,
sex, disease condition, and concomitant medications can be identified and their
relationship to the pharmacokinetic parameters quantified. Identification of
these factors and the modeling of their relationship to the specific
pharmacokinetic parameters is an important component of the population

2

approach and is valuable in allowing more rational dosage regimens in patients
(3). Also the population approach provides estimates of residual or intraindividual error due to random error and model mis-specification. Thus
population approaches is particularly useful for the study of intra- and interindividual variability.

In summary, the population approach to pharmacokinetic analysis is performed
to (i) estimate the mean pharmacokinetic (PK) parameters in a patient
population, (ii) investigate and identify patient characteristics as sources of
variability (covariates) which influence the PK of drug, (iii) estimate the
unexplainable interindividual variability, and (iv) estimate the random residual
variability (including intraindividual, measurement error).

Population Approach

There are two components to a population pharmacokinetic model. The first
part is the structural model, which characterizes the specific pharmacokinetic
model and the relationship of the pharmacokinetic parameters to the patient
characteristics. The second part is the statistical model, which quantifies
unexplainable variability of the data (4).
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The population model will be explained using a simple example using onecompartment model for IV bolus input:
Cpj

=D e -CL tj

v

v

(Eq.1)

Where Cpj is the observation at time j, as a function of dose (D), volume of
distribution (V), time (t) and clearance (CL). Note CUV

= k.

It is recognized

that the value of each parameter will vary in a population.

Various models can be used to describe parameter variability. The simplest
model is for additive error:

C~

Where

C~

=CLpop + Tl

(Eq.2)

is the CL in individual 'i' and CLp0 p is the population mean. The

parameter eta (T}) represents difference between CLi and CLpop· Every
individual in the population has a specific value for their pharmacokinetic
parameter, which will differ from the population typical value due to
unexplainable variability, which is quantified by using the parameter eta (rt). It
is assumed that rt is normally distributed with a mean of zero and Standard
deviation of w. Similar models can be used for V.

(
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Additional models can be used to explain the difference between the predicted
and measured concentration in an individual. The difference between the
predicted and measured concentrations is due to residual or intra-individual
variability. Again the simplest model for this type of variability is an additive
model, which has the form:

Cpi,j

= Cpmij + c

(Eq. 3)

Where E (Epsilon) represents the difference between the model predicted
concentration (Cpmij) in individual i at time j and the actual plasma
concentration (Cpij) in individual i at time j. Again Eis assumed to be normally
distributed with a mean of zero and a standard deviation of cr.

Non-linear Mixed Effect Modeling (NONMEM)

The principle objective of modeling pharmacokinetic data is to find parameter
values that reduce the difference between the observed data and predicted data
(5). The relationship between concentration-time is non-linear; hence nonlinear modeling techniques are required to fit a line through the data to obtain
parameter estimates. A number of computer software packages have been
developed for population analysis and Non-linear Mixed Effect Modeling
(NONMEM) developed by Beal and Shiener (6) is most commonly used
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software in population studies. It uses a true population approach in that the
population parameters are determined in a single stage of analysis (7).

The term tnixed effects modeling is used to describe the modeling process
since two types of parameters ("effects") are estimated. The fixed effect
parameters are associated with the pharrnacokinetic model and the random
effect parameters describe the inter- and intra- individual variability associated
with the statistical model (8). The fixed effects are represented by the
population pharrnacokinetic parameters and covariates relating them to patient
characteristics.

Thus, fixed effects include the dose, clearance (CL) and

volume of distribution (V), and coefficients linking physiological factors such
as age, weight and creatinine clearance and other factors such as concomitant
medications to the pharrnacokinetic parameters (3) (8). In NONMEM the fixed
effect parameters are usually given the symbol theta.

Random-effect parameters quantify variability in the model arising from
interindividual (between subjects) and intra-individual (within subjects)
variation (3). Interindividual variability is the seemingly random between
subject variability in the pharmacokinetic parameters that cannot be explained
in terms of fixed effects. It is important to obtain an estimate of unexplained
variability for a new drug because of the safety and efficacy of a drug tends to
decrease as the unexplained variability in its pharrnacokinetic parameters

6
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increases (4). Intra-individual or residual variability is the unexplainable
variability that occurs at the level of an observed plasma concentration. It may
arise from the measurement error, model misspecification, and random
variation in a patient's pharmacokinetic parameters that can occur over time
(3) (8) (9) (10).

NONMEM can be used to derive a population model from randomly collected
sparse data. The data from all individuals are pooled into one data set but
individuals are still identifiable and this permits different numbers of repeated
measures for the individuals. Once a population model has been derived a
Bayesian post-hoc step can be invoked to permit the estimation of the
pharmacokinetic parameters for each individual in the data set. The ability of
NONMEM to take advantage of sparse data makes it ideally suited for the
study of those populations where intensive sampling may be difficult and/or
unethical, such as the very old, very young or very sick (6). Output from
NONMEM includes estimates of mean variances and covariances of the
parameters (6).

7
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CY CLOS PO RINE

A group of compounds called cyclosporines were isolated from the soil as
major secondary metabolites of the fungus Tolypocladium infatum Garns
(formerly Trichoderma polysporum). These substances were initially found to
have antifungal activity. Cyclosporine A (CsA) is one of the major metabolites,
and it has revolutionized organ transplantation. CsA is a neutral, hydrophobic,
cyclic peptide containing 11 amino acids, (Fig 1) having a molecular weight of
1202.1, (C 62H 111 N 11 0 12). Rather than acting as a cytotoxic agent, which
defined the activity of a number of available immunosuppressive drugs at that
time, cyclosporine produces an immunomodulatory effect principally on the
helper/inducer (CD4) lymphocytes, which orchestrate the generation of
immune response.

Mechanism of Action

The exact mechanism(s) of immunosuppressive action of CsA has not been
fully elucidated but appears to mainly involve inhibition of lymphocytic
proliferation and function. It has been suggested that immunosuppressive
action of cyclosporine results from specific and reversible inhibition of the
immunocompetent T-cells in the GO (resting) or Gl (post-mitotic, or
presynthetic) phase of the cell cycle (11). CsA suppresses some humoral
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immunity but is more effective against T cell-dependent immune mechanism
such as those underlying transplant rejections and some form of autoimmunity
(12). It preferentially inhibits antigen-triggered signal transduction in T
lymphocytes, blunting expression of many lymphokines, including IL-2, as
well as expression of antiapoptonic proteins. Cyclosporine forms a complex
with cyclophilin, a cytoplasmic receptor protein present in the target cell. This
complex binds to calcineurin, inhibiting Ca++-stimulating dephosphorylation of
the cytosolic component of NFAT (nuclear factor of activated T-cell) (13).
When the cytoplasmic component of NFAT is dephosphorylated, it
translocates to the nucleus, where it complexes with nuclear components
required for complete T-cell activation, including transactivation of IL-2 and
other lymphokines genes. Calcineurin enzymatic activity is inhibited following
physical interaction with the cyclosporine/cyclophilin complex. This results in
the blockade of NFAT dephosphorylation; thus, the cytoplasmic component of
NFAT does not enter the nucleus, gene transcription is not activated, and the T
lymphocyte fails to respond to specific antigenic stimulation.

9
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Pharmacokinetics of Cyclosporine

Absorption and Bioavailability

CsA is absorbed in the upper part of the GI tract (14). Oral absorption of
cyclosporine is slow and variable. The extent of absorption depends on the
individual patient, patient population (e.g., transplant type), post transplant
time, bile flow, GI state, and the formulation administered. CsA is a lipophilic
drug and was first marketed in an oil-based formulation, Sandimmune®
(Novartis Pharmaceutical) in 1983. The absorption of CsA from Sandimmune
is associated with marked pharmacokinetic variability with large variation in
the area under the time-blood CsA concentration curve (AUC), Cmax and
Tmax (15). Emulsification of the crude oil-in-water droplet mixture formed on
contact with GI fluids by bile salts is necessary before cyclosporine can be
absorbed. Thus, the absorption is known to be highly dependent on bile
production and early graft dysfunction with poor bile production and the use of
external biliary drainage in patients lead to poor cyclosporine absorption (16)
(17). The poor and highly variable absorption of the drug from Sandimmune
hindered attainment of adequate cyclosporine concentration in the early post
operative period (18) (19) and has been shown to be important risk factor of
both acute and chronic rejection after organ transplant (20). The oral
bioavailability of Sandimmune varies between 1 and 89%, with a mean value

10

(

of around 30% (21) (22). As a result of the biliary emulsification step noted
above, the extent of absorption of Sandimmune can vary according to the
presence of food, bile flow and GI motility.

To overcome the problems of poor and variable absorption of cyclosporine
from Sandimmune, a microemulsion formulation Neoral®, was developed
(23). This formulation incorporates cyclosporine in a microemulsified
preconcentrate with a surfactant, lipophilic and hydrophilic solvents, and a
hydrophilic co-solvent. Using this preparation, cyclosporine is more rapidly
absorbed from the gastrointestinal tract so that blood concentrations reach a
higher Cmax within a shorter time than with the Sandimmune (Table 1). It was
found that following oral administration of Neoral, the time to peak blood
concentration (Tmax) is 1.5 to 2.0 hours compared to 3.5 hours for
Sandimmune (23) (25) (24). The dispersion of the microemulsion formulation
within the intestinal tract does not rely on emulsification with the bile salts;
hence CsA is absorbed more uniformly from Neoral than from Sandimmune.
Furthermore, several studies have also documented a significant reduction in
the incidence of acute cellular rejection in Neoral-treated versus Sandimmunetreated de nova renal (25) (26) liver,(27) (28) lung, (29) and cardiac (30)
transplant recipients. Neoral has shown to reduce the variability in the
gastrointestinal absorption of cyclosporine with an average bioavailability 30%
higher than that of Sandimmune (17).

11
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Administration with food both delays and decreases absorption . High- and
low- fat meals consumed within 30 minutes of administration decreases the
AUC by approximately 13% and maximum concentration by 33 %. This makes
it imperative to individualize dosage regimes.

Distribution

Cyclosporine is distributed extensively outside the vascular compartment. In
the body, cyclosporine accumulates mainly in fat-rich organs including liver,
adipose tissue and lymph nodes. After intravenous dosing, the steady- state
volume of distribution has been reported to be as high as 3 to 5 liters/kg in
solid organ transplant recipients. The drug is 98 to 99% bound to plasma
proteins, crosses the placenta, and is distributed into human milk. Of the 90 to
98% of circulating cyclosporine bound to plasma proteins, 85 to 90% is carried
on lipoproteins. Distribution of the cyclosporine within the whole blood is
dose-dependent with 33 to 47% of the cyclosporine being present in plasma, 4
to 9 % in lymphocytes, 4 to 12% in granulocytes and 41 to 58% in erythrocytes
(11). The distribution of cyclosporine in blood is highly temperature
dependent. It has been reported (31) that at 37°C, 60% of the blood
cyclosporine was localized in plasma compared with 46% at room temperature,
which may be due to high affinity of cyclosporine for plasma protein,
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including lipoproteins, at elevated temperatures (32). Due to this temperature
dependency, whole blood is presently the preferred matrix for the therapeutic
monitoring of total cyclosporine because storing the blood at different
temperatures does not alter the total concentrations in blood (33).

Elimination

In adults with normal renal and hepatic function, the initial elimination halflife has been reported to be an average 1.2 hours, with a terminal elimination
half-life of 8 to 27 hours (range 4 to 50 hours) (11). Clearance from the blood
is approximately 0.3 to 0.4Uhrfkg in adults undergoing renal or hepatic
transplantation, but is slightly lower after cardiac transplantation. Clearance in
infants appears to be several times higher than in adults and is approximately
doubled in older children (11).

Cyclosporine is extensively metabolized in the liver by the cytochrome-P450
3A (CYP3A) enzyme system and to a lesser degree in the gastrointestinal tract
and the kidneys(34). The metabolism of cyclosporine is influenced by liver
function. Pre-systemic extraction of cyclosporine is extensive after oral
administration and is a major cause of the low bioavailability of CsA.
Cyclosporine undergoes restrictive clearance and the pre-systemic extraction
primarily occurs in the GI mucosa (14). The metabolism of cyclosporine
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molecule involves mainly hydroxylation, demethylation and cyclisation of
different amino acids while the cyclic structure remains intact. Major
metabolic pathways that have been identified include hydroxylation of the Cycarbon of two leucine residues, C1..- carbon hydroxylation and cyclic ether
formation (with double bond oxidation) in the 3-hydroxy-N, 4-dimethyl-L-2amino-6-octenoyl group and N-demethylation of the N-methyl leucine residues
(11). Oxidation of cyclosporine yields the major metabolites AMl, AM4N and
AM9, which account for approximately 70, 21 and 7.5%, respectively of the
total AUC of cyclosporine.

Cyclosporine and its metabolites are excreted principally through the bile into
the feces, with only approximately 6% being excreted in urine. Only 0.1 % of
cyclosporine is excreted unchanged in urine (24). Cyclosporine is also excreted
in human milk.

Toxicity

The most important and clinically significant side effect of cyclosporine is
nephrotoxicity. The other principal adverse reactions to cyclosporine therapy
are tremor, hirsutism, hypertension, hyperlipidemia, and gum hyperplasia (14).
Nephrotoxicity is limiting and occurs in

the majority of patients.

Nephrotoxicity is characterized with increased BUN (Blood Urea Nitrogen)

14

and serum creatinine concentration, and have been observed in 25-32, 38, and
38% of patients receiving the drug for kidney, heart, or liver allografts,
respectively. Elevation of BUN and serum creatinine concentrations resulting
from cyclosporine therapy appear to be dose related, may be associated with
high trough concentrations of the drug, and are usually reversible upon
discontinuation of the drug. Mild cyclosporine-induced nephrotoxicity
generally occurs within 2-3 months after transplantation (11).

Mild to moderate hypertension also occurs in about 50% of renal transplant
recipients who receive cyclosporine and in most cardiac transplant patients
receiving the drug. Hypertension generally develops within a few weeks after
initiation of cyclosporine therapy and affects both systolic and diastolic blood
pressure. Tremors reportedly occur in 12-21, 31, or 55% of the patients with
kidney, heart, or liver allografts, respectively who receive cyclosporine.
Seizures (particularly when cyclosporine was used in combination with highdose corticosteroids), headaches, paresthesia, flushing, and confusion have
been reported occasionally in patients receiving cyclosporine.

Drug Interactions with Cyclosporine

Cyclosporine is metabolized by CYP3A4 and is a substrate of P-glycoprotein,
hence drug interactions exist with agents that inhibit these pathways or are
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cleared by these mechanisms. Drugs that induce cytochrome P-450 activity
could increase the metabolism of cyclosporine and decrease its concentration
in blood. Because of a large number of drugs interacting with cyclosporine,
complete avoidance of drug interactions with cyclosporine is very difficult.

Drugs that inhibit cytochrome 3A4 and/or P-glycoprotein and are known to
increase cyclosporine concentrations include: calcium channel blockers
(veraparnil, diltiazem, nicardipine), azole antifungal (fluconazole, itraconazole,
ketoconazole),

macrolide

antibiotics

(erythromycin,

clarithromycin,

troleandomycine), antivirals (indinavir, nelfinavir, ritonavir, saquinavir),
steroids (methylpredisolone, oral contraceptive, androgens), psychotropic
agents (fluvoxarnine, nefazodone), amiodarone, chloroquine, allopurinol,
bromocriptine, metoclopramide, cimetidine, grapefruit juice (11)(35).

Drugs that induce cytochrome 3A4 and/or P-glycoprotien and have been found
to reduce cyclosporine concentrations include: anti-microbials such as
nafcillin, rifampin and rifabutin, anticonvulsants (phenytoin, carbamazepine,
phenobarbital, prirnidone), barbiturates, arninoglutethirnide, troglitazone,
octreotide, and ticlopidine (35).

Other agents known to cause interactions with cyclosporine are drugs that
cause nephrotoxicity when administered alone. These include arninoglycoside
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antibiotics, vancomycin, cotrimoxazole (trimethoprim- sulfamethoxazole),
amphotericin B, and anti-inflammatory drugs (diclofenac, naproxen, and other
non steroidal anti-inflammatory drugs) (35).

Therapeutic Drug Monitoring of Cyclosporine

Cyclosporine's variable pharmacokinetics result in wide variation in the blood
concentrations achieved from a given dose of cyclosporine. Consequently
dosage optimization is

frequently

performed using therapeutic

drug

monitoring. Monitoring is necessary to achieve clinical efficacy and while
avoiding toxicity and maintain good tolerability.

Various approaches are used to monitor CsA (36).

These include: (i) the

measurement of trough concentrations (CO) (ii) the measurement of the area
under the blood concentration versus time curve (AUC), (iii) limited sampling
strategies, (iv) monitoring of concentrations at 2 hours post dose (C2), (v)
Bayesian forecasting, and (vi) pharmacodynamic monitoring. Trough (CO)
monitoring is the traditional approach of monitoring and involves measurement
of a single trough blood concentration of cyclosporine. It is simple to carry out
and is practical for routine clinical analysis. However CO has been found to be
a poor indicator of total drug exposure and not an accurate predictor of clinical
efficacy (37) (38). AUC monitoring is a more precise way to monitor, as it is a
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direct measurement of the extent of exposure to drug; it appears to predict
clinical outcomes and allows calculation of oral pharmacokinetic parameters
(20) (39). However it is impractical for routine clinical use, and is costly and
inconvenient to both clinician and patients (37) (38). Limited sampling
strategies represent a clinically feasible way to estimate AUC. A regression
equation, developed from AUC values in a sample population is used to
estimate subsequent AUC by sampling only 2-3 CsA concentrations at
optimum times. This method is limited by the validation and predictive power
of the equations generated (36). Monitoring of concentrations at 2 hours post
dose is considered as the most useful tool for monitoring. It closely correlates
with AUC0-4, the period of maximum intra-individual and inter-individual
variability, and C-2 monitoring is practical and convenient for clinical setting
(40)

(41).

The

Bayesian

forecasting,

involves

the

calculation

of

pharmacokinetic parameters in a patient by blending the patient specific drug
concentrations with pharmacokinetic and statistical models that have been
established for the particular patient population. However population databases
are not generally available for cyclosporine. Finally pharmacodynamic
monitoring has also been used and it involves the use of in-vivo markers of
immunosuppression. However it is not widely used because the assays are
cumbersome, and because of the difficulty in distinguishing rejection from
toxicity.
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Analytical Instrumentation for Monitoring Drug Concentration

Cyclosporine

1s

pharmacokinetics.

a

narrow

therapeutic

Consequently

index

therapeutic

drug

drug

with

variable

monitoring is

often

performed to individualize the dose to ensure optimum immunosuppressive
activity. Monitoring is done using whole blood because of temperature
dependency in blood-plasma ratio. The assays available for whole blood and
their associated therapeutic ranges include monoclonal radioimmunoassay
(range

75-325µg/L),

immunoassay

monoclonal

(mFPIA)

(range

antibody

fluorescence

100-400µg/L),

polyclonal

polarization
antibody

fluorescence polarization immunoassay (pFPIA)(range 200-800µg/L), enzyme
multiplied immunoassay technique (EMIT) (range 75-375µg/L) and high
performance liquid chromatography (HPLC) (range 100-325 µg/L) (35).
HPLC is used as a reference standard method for monitoring cyclosporine
concentration against which other analytical methods should be validated.

CYSTIC FIBROSIS

A varied amount of references are available in clinical textbooks (42), World
Wide Web (43) and journal articles (44) (45) concerning the clinical
physiology of cystic fibrosis. Cystic fibrosis (CF) is an inherited disorder that
affects the body's epithelial cells. Under normal circumstances, certain types
19
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of epithelial cells produce mucus and other watery secretions that coat the
passageways of the lungs , liver, pancreas, reproductive tract, and intestinal
tract. However, in cystic fibrosis inherited CF gene abnormalities cause these
epithelial cells to produce secretions that are much thicker than normal , this
abnormally thick mucus is due to the faulty transport of sodium and chloride
within cells lining the organs.

In the lungs of persons with CF, thickened secretions trap microorganisms and

encourage repeated lung infections. In pulmonary disease airways obstruction,
impaired mucociliary clearance, bronchiectasis, and chronic infection are
characteristic of CF and account for the progressive loss of lung function . This
is marked by an average decline in FEVl (is the forced expiratory volume in 1
second and determines the capacity of a person to breathe out in one second,
trying as hard as possible) of roughly 1.5-4% per year. Therapy is directed at
airway clearance, treatment of exacerbations, and management of airflow
obstruction. Lung transplantation is a final option for those patients with severe
progressive pulmonary disease.
Cystic fibrosis has a variety of symptoms. The most common are: very saltytasting skin; persistent coughing, wheezing or pneumonia; excessive appetite
but poor weight gain; and bulky stools. The sweat test is the standard
diagnostic test for cystic fibrosis. This simple and painless test measures the
amount of salt in the sweat. A high salt level indicates that a person has CF.
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The treatment of CF depends upon the stage of the disease and which organs
are involved. Antibiotics are also used to treat lung infections and are
administered intravenously, orally, and/or medicated vapors, which are
inhaled, to improve breathing.

Chronic infection in the airways is present in most patients with CF. The
clinical course of disease is marked by periods of stability which are
interrupted by exacerbations characterized by increased sputum production,
dyspnea, fatigue, weight loss, and decline in FEV 1. Exacerbations most often
result from bacterial infections. Staphylococcus Aureus and Haemophilus
Influenza are common pathogens in children. The prevalence of Pseudomonas
Aeruginosa rises during childhood and adolescence so that 80% of CF patients
are infected with Pseudomonas by age 18. Aggressive treatment of infection is
the recommended approach, and in the adult therapy is mainly targeted at
Pseudomonas. A typical antimicrobial regimen consists of intravenous
tobramycin and an anti-pseudomonal penicillin or cephalosporin. Antibiotics
are tailored to the results of each individual's sputum culture.

Bilateral lung transplantation remains an option for severe progressive
pulmonary disease. An FEVl of 30 percent predicted, frequent hospitalizations
and pulmonary hypertension are generally used in the decision to refer for
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transplantation. Although transplantation offers the only potential life saving
therapy, the procedure is not without risks as 5-year survival is just under 50%.
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Figure 1.1. Chemical Structure of Cyclosporine
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Table 1.1. Comparative pharmacokinetics of Sandimmune and Neoral
formulation of cyclosporine

Neoral
AUC µg/L.h)
a.
b.
c.
Cmax (µg/L)
a.
b.
c.
Tmax (h)
a.
b.
c.
Crnin (µg/L)
a.
b.
c.

Sandimmune

18.17
24.4
3525

13.29
16.3
2556

4.09
6.2
721

2.60
4.7
422

1.69
1.7
1.5

2.7
4.5
2.8

0.67
NA
151

0.55
NA
121

Reference: a=Kahan et al (46); b=Keown et al (47); c=Keown et al (25)
AUC shown are at 12-hour intervals.
AUC= area under the blood concentration versus time curve for
cyclosporine; Cmax= maximum blood concentration of cyclosporine;
Crnin= minimum (trough) blood concentration of cyclosporine; Tmax=
time to Cmax
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MANUSCRIPT II
ABSTRACT

Cyclosporine (CsA), a potent immunosuppressive agent has markedly
improved the graft survival rate, but owing to its narrow therapeutic index the
clinical use of cyclosporine is complicated by large intra- and interindividual
variabilities in its pharmacokinetics, and consequently it is necessary to
individualize the dose for each patient. Many factors such as patient age,
gender, time post transplant, concomitant medication, presence of certain
disease conditions like cystic fibrosis (CF), ethnic origin and gastrointestinal
status have been believed to influence cyclosporine pharmacokinetics. The
population pharmacokinetic analysis is ideally suited to study the variability of
CsA

pharmacokinetics

within

the

patient

population.

Additionally,

cyclosporine is available in two formulations: Sandimmune, an oil based
preparation, and Neoral, a microemulsion formulation, which display different
pharmacokinetic profiles.

Non linear mixed effect modeling (NONMEM) was used to perform
population modeling of CsA on blood samples obtained from 48 thoracic
transplant patients. Samples were collected at weeks 1, 2, 3, 4, 13, 26, 39 and
52 post transplant. In general each individual provided 3 blood samples per
visit at approximately time 0, 2 and 6- hours post dose. For the analysis a onecompartment model with first order absorption was used to describe the model.
31

The value of absorption rate constant (ka) was fixed due to a limited number of
blood samples in the absorption period. An exponential error model was used
to describe inter-individual variability in oral clearance (CUP) and a
proportional error model was used for residual variability. Itraconazole and
cystic fibrosis were found to be significant covariates for CUP. The type of
formulation and time post-transplant were identified as significant covariates
for bioavailability. The final model estimates for CUP were 26.4(± 3.7) Uh. In
the presence of itraconazole or cystic fibrosis the estimates of clearance were
11.6 (± 4.3) Uh and 52.3 (± 6.9) Uh , respectively. The bioavailability of
Sandimmune was found to be 87% that of Neoral. During the first four weeks
after transplant, in which a linear model was assumed, bioavailability was
64.5% that in subsequent weeks. The volume of distribution was 183 (± 37) L.
The estimates of CV for the final model for interindividual variability on CUP
were 18.5% and for residual variability 49.6%.
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INTRODUCTION

Cyclosporine (CsA) is a potent irnrnunosuppressive agent, widely used to
prevent graft rejections. Cyclosporine has markedly improved the graft
survival rate, but owing to its narrow therapeutic index and it highly variable
pharmacokinetics, a whole blood monitoring of CsA concentrations is
commonly performed to individualize the dose in patients (1). Cyclosporine
was initially formulated under the brand name Sandirnmune® as an oil based
formulation which successfully reduced the incidence of acute rejection in
transplant patients, but this formulation was associated with high inter- and
intra- patient variability and poor and variable bioavailability (2)(3), and
attainment of adequate CsA level was particularly difficult. A microemulsion
formulation of CsA, Neoral® was developed to circumvent some problems
· associated with Sandimmune (4). Cyclosporine is more rapidly absorbed from
Neoral, which has a higher Cmax and shorter Tmax.

Due to the presence of marked intra- and inter-individual variability in CsA
pharmacokinetics and the serious consequences of plasma concentrations
outside the therapeutic range, there is a general consensus that a
pharmacokinetic approach be used to optimize therapy (1)(5). Traditionally,
trough levels of CsA are monitored (5). However this parameter does not
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adequately reflect the overall exposure of the patients to CsA other methods
have also been proposed. These include the blood concentration two hours
after dose (C2) and the measurement of area under the concentration-time
curve (AUC) (5). However, the latter method requires the collection of a series
of blood samples and is impractical in clinical practice. To overcome this
disadvantage a Bayesian approach using a limited sampling method in
conjunction with a population pharmacokinetic model has been proposed (6).

Many factors are believed to influence cyclosporine pharmacokinetics.
Cyclosporine has a highly variable absorption, which is dependent on liver
function, bile flow , time post transplant and gastrointestinal status (3). The
distribution of CsA is mainly influenced by lipoprotein concentration in
plasma. However, age, gender and obesity do not appear to be important
factors for distribution. Metabolism of CsA can be influenced by the use of
concomitant medication, and other factors such as presence of certain disease
conditions like cystic fibrosis, and ethnic origin (3).

Cyclosporine is metabolized primarily by cytochrome P450 3A4 in the liver
and small intestine. Cyclosporine is also a substrate of p-glycoprotein (which
acts as a counter-transport pump, actively transporting cyclosporine back to the
intestinal lumen). Unexpected drug interactions can lead to sub-therapeutic
dosing in case of enzyme inducers, or drug toxicity with enzyme inhibitors.
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Itraconazole appears to inhibit both cytochrome P450 3A4 and p-glycoprotein.
Back et al (7) conducted an in-vitro study using human liver enzymes to
examine the ability of antifungal drugs to inhibit the metabolism of CsA. They
found out that ketoconazole was the most potent inhibitor of CsA; itraconazole
was the next potent, and fluconazole the least potent inhibitor of cyclosporine
metabolism. Inhibitory effects of itraconazole have also been demonstrated invivo (7). Concomitant administration with CsA increased whole blood or
serum concentration of CsA and serum creatinine concentrations.

Cystic fibrosis (CF) affects the mucus and sweat glands of the body and is
caused by a defective gene. Thick mucus is formed in the breathing passages in
the lungs and this predisposes the person to chronic lung infections. Lung
transplant is the treatment of choice for patients with end stage cystic fibrosis.
This disease has been found to alter the pharmacokinetics of CsA. These
patients

exhibit

poor

absorption

that

may

lead

to

ineffective

immunosuppression and subsequent graft rejection. Patients with CF usually
have fat malabsorption due to pancreatic insufficiency and require treatment
with pancreatic enzyme supplements (8). Despite such therapy, the absorption
of CsA from Sandimmune, which is a lipophilic immunosuppressive agent, has
been found to be reduced in CF patients (8). The absorption of CsA from
microemulsion formulation Neoral appears less affected by CF (9). Cystic
fibrosis patients undergoing heart and lung transplant require a higher dose of
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CsA

and frequent

monitoring

of blood level

to

achieve

adequate

'
immunosuppression. In a study by Tan et al. (10) the apparent oral clearance of
CsA was found to be about twice as high in patients with CF than in patients
without CF. This increase could, however, be caused by the poor
bioavailability of the drug which has been suggested in patients with CF by
Cooney et al.(11). Other drugs that have shown elevated clearance when
patients have CF include theophylline, ciprofloxacin, sulfamethoxazole and
ibuprofen (11).

Kahan et al. (12) showed patient's age over 45 years had lower CsA clearance
and male and female patients were shown to differ significantly in their ability
to clear and distribute CsA. Ethnic background was found to influence the
bioavailability of Sandimmune. Lindholm et al., (13) found the bioavailability
(F) of CsA to be significantly lower in black patients than in white patients

(mean values of 30.9% ± 12.3% and 39.5% ± 16.5%, respectively; p < 0.001).
The study found that these racial difference in F may contribute to the poorer
outcome observed after kidney transplantation in black patients. However in a
controlled study done on healthy African American and white volunteers by
Stein et al., (14) no difference in pharmacokinetic parameters were found
between the ethnic groups for Sandimmune and Neoral. However compared to
Sandimmune, Neoral resulted in an approximately 60% higher Cmax. a 50%
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greater AUC, and a 25% lower oral clearance in both African American and
white subjects.

An understanding of factors that modify CsA pharmacokinetics, particularly its
bioavailability and clearance is important in order to better predict the
optimum dose for a patient. This study describes the application of the
population approach to pharmacokinetic analysis to the study of the
pharmacokinetics of CsA in thoracic transplant patients.

MATERIALS AND METHODS

Study Design:

Population pharmacokinetics of CsA were studied using data obtained from a
previously published study (15). A randomized, open-trial study was
conducted on heart and lung transplant recipients receiving either Sandimmune
or Neoral as immunosuppressive therapy during the first year of transplant
conducted at Papworth Hospital, Cambridge, UK. The Local Ethics Committee
approved the study and approval from the Institutional Review Board (IRB) at
The University of Rhode Island was obtained to re-analyze the data. In brief,
blood samples were collected from 48 patients aged 19 to 66. The group
consisted of 26 males and 22 females who had undergone either single lung
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(18 patients), double lung (9 patients), or both heart and lung (21 patients)
transplant. Twenty-one patients received Sandirnmune and 27 patients were
administered Neoral. Patients with cystic fibrosis (CF) were randomly selected
independently because of unusual pharmacokinetic in CF patients. Patients
with CF received their daily oral CsA at 8-hour intervals rather than the usual
12-hour interval.

Immediately

following

methylprednisolone

and

transplant,
rabbit

patients
antithymocyte

received
globulin

intravenous
induced

irnmunosuppressive therapy was given to all the patients, followed by
maintenance triple- therapy with oral cyclosporine, azathioprine, and
prednisolone. A dose of 50 mg of Sandirnmune or Neoral was administered to
the patients on the first day of their transplant and increased by 50 mg at each
12- hourly dose until therapeutic trough levels were achieved. Therapeutic
goals for the trough levels were 300-400µg/L for months 1 and 2 and 200 to
300µg/L for months 3 and 12.

Pharmacokinetic Protocol and Analytical Method

The data collected over 12 month period was stored in a computer database.
Patients had blood samples drawn for analysis of CsA concentration during
clinical follow-up visits at weeks 1, 2, 3, 4, 13, 26, 39 and 52. In general each
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individual provided 3 blood samples per visit: at approximately time 0- (Co), at
2- (C 2) and 6- hours (C 6) post dose.

Blood cyclosporine concentrations were monitored by Dade-Behring Emit
2000 immunoassay (Dade-Behring Diagnostic UK, Ltd.; Milton Keynes, UK).
Special care was taken to ensure that the trial database only included
cyclosporine measurements taken under steady state conditions.

Data Presentation and Pharmacokinetic Analysis

Clinical, pharmacokinetic, and demographic data including dose of CsA, CsA
blood concentrations, age, body weight, time post transplant (TPT), type of
formulations given, concurrent medications and disease condition relevant to
the population analysis, were extracted from the raw data sets and merged and
formatted using Microsoft® Excel 2000. The concentration time data were
tabulated for completeness and consistency of recorded sampling and dosing
time and prepared along with the relevant demographic data for analysis.

The pharmacokinetic analyses were performed using NONMEM (version V,
double precision) (S.L. Beal and L.B . Sheiner, NONMEM users guide,
NONMEM Project Group, University of San Francisco, San Francisco).
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Pharmacokinetic Model

A one-compartment model with first order absorption was used (ADV AN2 and
TRANS 2) and was parameterized as the first order absorption rate constant
(ka), apparent clearance (CIJF) and apparent volume of distribution (V!F).
Since a limited number of blood samples were collected during the absorption
phase, the absorption rate constant (ka) could not be estimated and was fixed;
the fixed values were be taken from previously reported population values
(16): 1.35h-1 and 0.25h-1 for Neoral and Sandimmune, respectively. The
relative bioavailability (F) of Sandimmune compared to Neoral was also
estimated.

Statistical Model

Additive, proportional or exponential error models were used in developing the
population model for interindividual variability in the pharmacokinetic
parameters of CIJF, V!F and Ka.
The models were:

9i = 9' +llai

For additive-error model,

9i = 9' [1 + (llai)]

For proportional-error model and

9i =9' exp Criai)

For exponential-error model
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Where Si is the estimate for a pharmacokinetic parameter in the ith individual,
8' is the population mean of the pharmacokinetic parameter, and flei represents
the random variable with zero mean and variance w2 that distinguishes the ith
individual pharmacokinetic parameter from the population mean value
predicted by the regression model.

Both proportional error model and combined additive- and proportional- error
model were used to model residual variability (including intraindividual
variability). The equations used are

Cij

= C'ij (1 + Elij)

For proportional error

Cij

= C'ij (1 +

For combined proportional- and additive-

Elij)+ E2ij

error models
Where

Cij

is the observed serum concentration of the ith individual at time j,

C'ij

is the predicted serum concentration of ith individual at time j, and

E2ij

are the component of proportional and additive errors with zero mean and

Elij

and

variance cr2 .

Data Analysis Strategy

The pharmacokinetic and statistical models were evaluated to determine the
basic model that best fit the data. A statistically significant decrease (P<0.05)
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m the minimum value of the objective function (as measured by the log
likelihood difference) was used as the criteria to determine the best model.
Initially, the population pharmacokinetic analysis was conducted without
including any covariates in the model (basic model). After a basic model was
identified, a model building process was employed to examine the influence of
patient covariates on the estimates of pharmacokinetic parameters. The effects
of the following patient covariates on CUF and V!F were evaluated: age,
weight, sex, formulation type (Sandimmune or Neoral), presence of cystic
fibrosis, type of transplant (single lung, double lung and heart and lung), time
post-transplant and use of concomitant medication. Age, weight, time posttransplant were examined as continuous variables. Sex, formulation type,
presence of cystic fibrosis and use of itraconazole as a concomitant medication
were examined as categorical variables.

A decrease in the minimum value of objective function of 3.841 or greater
following introduction of a single covariate into the model was considered
statistically significant (P<0.05 with 1 degree of freedom) using the

x2

distribution if the 95% confidence intervals (Cl) for the estimate did not
include null value. If the change in the objective function was 3.8 or greater
but the 95% CI for the estimate included the null value, the effect of the
variable was considered to be of borderline significance and that the covariate
was not included in the full model. It was assumed that no significant
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interaction between covariate factors existed. If there was an interaction
present for an effect that was not significant alone at the P<0.05 level, then the
effect would be minor and would not likely to be of clinical significance. Thus,
covariates effects were introduced individually and no covariate - covariate
interactions were modeled. For the significant covariates the improvement in
fit was assessed by the precision of the parameter estimate (standard error of
the mean and 95% confidence interval) and by the reduction in interpatient and
residual variability. In addition, scrutiny of the scatter-plots of weighted
residual (WRES) vs. cyclosporine predicted concentrations (PRED) was
another indicator of the goodness of fit in each model.

All significant variables were included in the full model and a backward
elimination process was then employed to eliminate covariates from the full
model in order to develop the final model. Backward elimination was
performed by removal of a covariate from the full model one at a time and
increase in the objective function of 6.68 or greater (P<0.01 with 1 degree of
freedom) on removal of a covariate from the full model signified that the
variable was important, and that covariate was retained in the final model.
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RESULTS

All error models (additive, proportional, exponential, and combined additive
and proportional models) were tested to account interindividual variability in
the pharrnacokinetic parameters (CUF and VIF) and residual error. An
exponential model for inter-individual variability in the pharrnacokinetic
parameters and a proportional error model for residual variability best
described the error models. A null value for the 95% confidence interval was
observed for interindividual variability in VIF, and hence the error term was
deleted in case of VIF for all further data analysis, in accordance with the data
analysis strategy.

A scatter plot for observed versus model-predicted cyclosporine concentration
is shown in Figure 2. The mean parameter estimates (95% CI are in
parentheses) obtained from the analysis of base model is as follows (Table 4):
CUF 23.lUhr (± 3.3 Uhr); VIF 202 liters (± 43 liters). The estimates for

coefficient of variation (CV) for interindividual variability on CUF were
32.1 % and for residual variability 60.1 %.

After the base model was completed, the influence of covariates was studied
on both CUF and VIF individually, and since ka was kept constant, none of the
covariates were estimated for ka. In the model building process the covariates
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were added to the base model one by one and those covariates which were
found to have reduced the value of objective function (used as a measure of
"goodness of fit") significantly (P<0.05) when tested against the base model
for both CIJF and V!F were considered to be used in the final model building.

Age and type of transplant (single lung, double lung, heart and lung) were not
found to be significant covariates for either CIJF or V!F (Table 2). Weight was
found to be a significant covariate for CIJF but not V!F. However a null value
was observed in the 95% confidence interval of CIJF (Table 2). Thus weight
was not considered for the final model, in accordance with the data analyzing
strategy.

Time post transplant (TPT) in weeks as a continuous covariate was not found
to be statistically significant on CIJF. Analysis of the graph of the post-hoc
values of CIJF versus time post transplant revealed a pattern which suggested
decrease in CIJF over the first four weeks. Hence, time post transplant was
modeled as a covariate for the first four weeks according to the formula Fl

=

1- Theta (5)/ TPT as shown in appendix. Modeled in this way time post
transplant was found to be a significant covariate (Table 2). Estimate of the
covariate for TPT on F for the first four occasions was 0.509!TPT (±0.076),
hence TPT was used in the final model building process.
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In the analysis of the potential influence of gender on CUF and V/F, male

patients were assigned "1" and females "O". Gender was added as a covariate
according to the formula TVCL= Theta (1) + Theta (5)*Sex. No significant
change was observed in objective function when gender was modeled for V/F.
The change in objective function (160.88) was significant (p<0.05) on CLIP
and was used for the final model building process. The estimate of CLIP for
gender was 28.6Uh for male and for females 18.3 Uh (±5.2) (Table 2).

ltraconazole was modeled as a categorical variable. A value of "O" was
assigned to patients not taking itraconazole and "1" to patients taking
itraconazole. On the assumption that itraconazole would reduce the CLIP of
CsA, itraconazole was modeled as a negative function according to the
formula: TVCL= Theta (1) - Theta (5)*1tra. Concomitant itraconazole was
found to be a significant covariate for CLIP (Table 2). The estimates for CLIP
obtained for patients with itraconazole in their therapy are 11.7 Uh and
without itraconazole the estimates for CLIP were 28.0Uh, a decrease in CLIP
by 58.2% (Fig 5). The estimates for coefficient of variation obtained for
interindividual variability on CL was 31 % (Table 2) and residual variability
51.7%. ltraconazole was also studied on V/F and no significant difference in
objective function was seen and hence not considered to be used in the final
model for V/F.
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Cystic fibrosis was evaluated by assigning patients with CF as 1 and patients
without CF as 0. Cystic fibrosis was found to be a significant covariate for
CLJF (Table 2). The estimates for CLJF when patients have CF and when they

do not have CF are 54.4 Uh and 21.7 Uh respectively; evident that presence of
CF increase the value of CLJF by 60% when compared to patients without CF.
The coefficient of variability for interindividual error on CLJF was 23.7%
(Table 2) and residual variability 60.6%. Cystic fibrosis was also analyzed on
V/F, but no change in objective function was observed, hence not considered
for final model. It was not possible to obtain estimates for cystic fibrosis when
studied as a covariate on bioavailability (F), but when the different
formulations (Sandimmune and Neoral) were included in the model, CF was
found to be a significant covariate for F of Sandimmune and Neoral. However,
when CF was included as a covariate for CLJF rather than F (on Sandimmune
and Neoral), a more significant result was obtained. The use of CF as a
covariate for CUF resulted in a more significant effect (Table 2) than when it
was used as a covariate for F (on Sandimmune and Neoral). It was found that
CLJF accounted for a significant change in objective function by 265.80 from

the base model; however modeling of CF on F (on Sandimmune and Neoral)
was not used in the final model along with CF on CLJF as it was assumed that
F would nullify the effect as we had modeled CF on CLJF previously and it
was found more significant. It was not possible to model CF on both CLJF and
Fin the model. However just for the records when the analysis using CF on F
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for both Sandirnrnune and Neoral was done, along with CF on CIJF a null
value was obtained in the estimates of 95% CI for both Sandirnrnune and
Neoral, which further confirmed our assumption of not using CF on CUF and
F together. Thus in the final model CF was used as a covariate for CUF.

Formulation (Neoral or Sandirnrnune) type was found to be a significant
covariate for F. Formulation type was also modeled using categorical
variables; Neoral was assigned a variable "O" and Sandirnrnune "l". The
model had the form Fl= 1*Dose+ Theta (5)*(1-Dose). The estimate of Theta
(5) were 1.39 (±0.45) which showed that the bioavailability of Sandimmune is
72% that of Neoral. The estimate of interindividual variability for CIJF was
30% (Table 2) and residual variability 62.4%.

To summarize, the following were identified as significant covariates for CIJF
body weight, gender, cystic fibrosis as disease condition, itraconazole as
concomitant medication, type of formulation (Sandimmune or Neoral), and
time post transplant (Table 2). The covariates which were not significant were
age and type of transplant (single lung, double lung or heart and double lung).
Weight had a null value in the estimate and was not included for final model
building, inspite of a significant change in objective function. Significant
covariates were only found for when analyzed for clearance (CIJF), no
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significant change was observed in the value of objective function when
covariates were analyzed for volume of distribution (V/F).

Consideration of the above significant covariates during model building also
resulted in improvement in the relationship between observed and modelpredicted concentration and weighted residuals versus model-predicted
concentrations. A reduction in the percentage value of residual random error
when compared to the base model also indicated a better model fit (Table 2). A
plot of observed and model-predicted concentration and weighted residual
versus model predicted for the base model is shown in Figure 2 (a) and (b)
respectively.

A full model was then developed containing all the significant covariates.
Backward elimination was then performed to identify the covariates for the
final model. The criteria for significance was a measure of change in objective
function value greater than 6.6 (p<0.01, with one degree of freedom) when a
covariate was removed from the model. As a result of this process gender was
eliminated from the model. The covariates CF, itraconazole, time post
transplant and use of different formulation were retained and added to the final
model (Table 3). The final model estimates for CUF were 26.4(±3.7), when
itraconazole was in therapy the estimates were 11.6 Uh (±4.3) and when
patients had cystic fibrosis 52.3 Uh (±6.9), as per the final model analysis.
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This showed a decrease in CUF by 58% when patients were on itraconazole
without CF, an increase of 51 % when patients had CF and no itraconazole in
therapy and an increase of 32% when patients had CF and were on
itraconazole. For the final model the estimates for different formulation of
Sandimmune and Neoral obtained were 1.14 (±0.18), showing bioavailability
of Sandimmune 87% that of Neoral, similarly the estimates for TPT for the
first four weeks were 0.355 (±0.107). The estimates of CV for interindividual
variability on CUF were 18.5% and residual variability 49.6% (Table 3). The
final model resulted in a better correlation of predicted versus the observed
concentration when compared with the base model, also a better correlation
was seen on scrutiny of weighted residual versus predicted concentration for
final model when compared with the base model (Figure 6a. and 6b.).

DISCUSSION

The objective of the study was to estimate apparent clearance (CUF) and
apparent volume of distribution (V/F) of CsA in patients who have undergone
heart lung transplantation and to identify patient's characteristics that
influenced these pharmacokinetic parameters. This would permit more rational
dosing of CsA and would assist physicians develop initial dosing regimens in
patients who have characteristics known to influence CsA pharmacokinetics.
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A one-compartment model best described the data. Others have found that CsA
pharmacokinetics are best described by a two-compartment (17). It is likely
that the limited number of blood samples especially during the distribution
phase made it impossible to fit the data to a two-compartment model.

The estimates of CUF and V/F obtained for the base model were 23.1 Uhr (±
3.3 Uhr) and 202 liters (± 43 liters) respectively, which is in good correlation
with literature values of 28.lUh and 280L for oral clearance and volume of
distribution respectively (18). It was not possible to include a term for the
inter-individual variability of V/F. This is probably because of the paucity of
informative data during the initial period following the dose. Consequently, the
inter-individual variability in V IF could not be studied.

Gender has been found to influence the CYP3A4 activity. Hunt et al (19)
found the hepatic CYP3A4 activity to be 24% higher in females than males.
Furthermore, when considered alone gender was found to be significant,
ultimately gender was not found to be significant in this study where 54%
patient were male.

Time post transplant is thought to affect bioavailability rather than apparent
clearance. In a study by Parke and Charles (20) postoperative day was modeled
on clearance, but was not found to be statistically significant, but when
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modeled on F, a superior fit to the data was obtained with use of mathematical
formulae. In this study also time post transplant was found to be significant
when it was modeled on F. On plotting a graph (Fig.I) between normalized
clearance (clearance in first week divided by clearance in following weeks)
and time post transplant it was observed that CUF decreased in the first four
weeks and then stabilize over time, hence it was modeled for the first four
weeks post transplant. However to be sure, runs were performed in which
CIJF was allowed to decrease over periods of 3 and 12 weeks; however the
best results were observed when the CUF was allowed to decrease over a 4
week period. A mathematical formula was derived which accounted for the
first four occasions. Estimates obtained were in agreement with previous
studies that states that the bioavailability of CsA decreases in the 2-3 weeks
after transplantation and then stabilize (14) (21).

Comparisons of Neoral pharmacokinetics to Sandimmune formulation have
been well documented (22) (23). Studies have shown Neoral to be a better
predictor of exposure and associated with reduced variability when compared
to Sandimmune. In the previously published study (14) conducted on the same
patients as this study, Neoral was associated with a higher and more consistent
exposure compared to Sandimmune. The lower bioavailability of Sandimmune
is in agreement with other studies, although the relative bioavailability of
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Sandimmune (0.87) compared to Neoral is somewhat larger than that published
in other studies (17) (22) (24).

Cyclosporine absorption and consequently blood concentration may vary
significantly according to bile flow, co-administration with food, GI tract
motility, renal function, and several drugs that patients may receive after
transplantation (25). Several of these factors are particularly important to
patients with CF. In CF, hepatobiliary involvement and alterations in bile flow
are common, and can change in severity in any individual (26). Bile acid is
required for micellar solubilization with Sandimmune, whereas Neoral is a
microemulsion that avoids bile salt dependence. In this study, presence of CF
as a disease condition increased CUF when compared to non-CF patients. This
observation has also been found by others (27). Patients with cystic fibrosis
undergoing lung transplant have been found to absorb Sandimmune
cyclosporine poorly (7). Neoral however has shown to provide better
absorption and produce higher drug exposure in both heart and lung transplant
recipients when compared to Sandimmune (8) (28). In this study eight patients
had cystic fibrosis of which 3 patients took Sandimmune and 5 patients took
Neoral. It was observed that in the CF patients Sandimmune showed a larger

CUF than Neoral (Fig. 3). This is probably the result of a lower F in patients
taking Sandimmune. In a study on CF patients by Reynaud-Gaubert et al, they
demonstrated a higher and more reliable bioavailability with less intrapatient
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variability from Neoral when compared to Sandimmune (27). In the present
study no definite results could be obtained for the change in bioavailability in
patients with CF on Sandimmune or Neoral. The relationship of different
formulations (Neoral and Sandimmune) on CF and non-CF patients was
initially performed. The estimates obtained for CF when patients were on
Neoral was 0.52, and 0.193 when on Sandimmune. Similarly the estimates for
non-CF patients for Neoral and Sandimmune were 1.85 and 0.193 respectively.
However, when this model was added for final model building, a null value
obtained, further analysis was not performed as no significant and reliable
results could be obtained from the comparison.

The potential for significant drug interactions is well recognized for CsA (3)
(16) (29) because it is a substrate for cytochrome P-450 3A4 and Pglycoprotein (30). ltraconazole is a CYP P-450 inhibitor has been shown in
previous studies (31) (32) to influence cyclosporine pharmacokinetics by
decreasing clearance. This was confirmed in the present study. The population
approach to the analysis of pharmacokinetic data is useful for identifying and
quantifying clinical significant drug interactions without the need for
controlled clinical investigation (33) (34). Using the population approach it is
possible to assess the clinical importance of drug interactions in patients
administered drugs as part of clinical therapy. However it is difficult to
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interpret information that suggests a lack of interaction because of problems
assigning the statistical power comparison using a population approach.

A relationship between age and changes in CsA pharmacokinetics was not
found to be significant, possibly due to the patient population belonging to a
limited age category (range 19-66). Burckart et al (35) did show an increase in
clearance in pediatric liver transplant (1-5 years) showing that clearance of
CsA may be several times higher in infants and up to twice as high in children
than adults, however no study has shown the influence of adult age as a
significant covariate on clearance.

There are no reports in literature to support type of transplant affects CsA
pharmacokinetics, and this study found no relationship between type of
transplant and CUF. There has been a mixed response in order to ascertain the
influence of weight on the pharmacokinetics of CsA. Certain authors (36)
found weight not to influence the pharmacokinetics of cyclosporine, but others
have found weight to be a significant covariate when modeled on CUF and
V/F(20). In this study weight did have a significant change in objective
function for CUF, however the CI of the estimates for weight involved a null
value and hence was not considered significant and was not used for final
model building. Weight was not identified as a significant covariate on V/F. It
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is possible that the low number of patients and the limited weight range (39.688 kg) made it difficult to adequately assess the significance of this covariate.

In conclusion the population pharmacokinetics of cyclosporine in heart and

lung transplant recipients was studied. Several patient characteristics such as
concomitant itraconazole, presence of cystic fibrosis, different formulation of
cyclosporine, and time post transplant were found to influence the
pharmacokinetics of cyclosporine. It was found that during the first 4 weeks
post transplant oral clearance decreased probably because absorption increased
over 4 weeks time, concomitant itraconazole decreased oral clearance by
43.9%, patients with CF has oral clearance higher by 50% than non-CF
patients, and the bioavailability of Sandimmune was 87% that of Neoral. The
presence of one or all of these covariates has been found to change the
pharmacokinetics of cyclosporine and hence care should be taken when
selecting a dosing regimen for patients with these characteristics.
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Table 2.1. Demographic Characteristic of the Patient Population

Characteristics of the Population
N=48

Mean Age (years)
Mean Total Body Weight
(Kg)
Gender
Male
Female
Total Samples
Samples per patient t
Formulation
Sandimmune
Neoral
Cystic Fibrosis
Concomitant ltraconazole
Cystic Fibrosis and
Concomitant ltraconazole

42 (range 19-66)
58.7 (range 39.6-88.0)

N=26
N=22
1004
21 (3-24)
21
27
8
11
3

Transplant Type
Single Lung
Double Lung
Heart and Lung

18
9
21

t 3 blood samples were obtained during a dosing interval at 0, 2 and 6 hours
after dose. This was repeated for a maximum of 8 times over the course of a
year.
:j: Non-cystic fibrosis patients received cyclosporine (25-450mg) every 12-hour

Cystic fibrosis patients received cyclosporine (100-500mg) every 8-hour.
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Table 2.2. Summary of Analysis of Covariate Effect Tested on CUF

Covariates

Model

OBJ

i'.lOBJ

% CV Significant
(P=0.05)

Base

TVCL= 8 (1)

-456.97

N.A

32.1

N.A.

ltraconazole

TVCL=81 + 85*1tra

-1013.81

556.84

31

Significant

Cystic Fibrosis

TVCL=81+85*CF

-739.75

282.02

23.7 Significant

Formulation

Fl=l *FORM+85 *(1FORM)
TVCL=81+85*SEX

-517.67

60.70

30.0 Significant

-617.85

160.88

33.2 Significant

Gender
Time Post
Transplant
WeightT

Fl= 1- 85 I TPT

-680.30

223 .33

30.0 Signjficant

TVCL=81+ 85 *WT

-549.22

92.24

32.1 Significant

Age

TVCL=81+85*Age

-456.97

0

Type of
Transplant

TVCL=81 +85*TYPE

-457.35

0

32.1

Not
Significant
32.1
Not
Significant

t Not included in the Final Model since estimate involved a null value in 95% CI
Itra = ltraconazole. Patients on Itraconazole= 1, patients without itraconazole = 0
CF= Cystic Fibrosis. Patients with CF=l, patients without CF=O
FORM= Formulation. Neoral=O, Sandimmune=l
Male= 1, Female=O
WT= Weight in kilograms
TPT= Time post transplant converted in weeks
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Table 2.3. Backward Elimination of Significant Covariates to Build the Final
Model
Full
Model

No Itra

No CF

MOF

-1369.92

-1012.86

-1164.06

-1356.65

81 CUF
Uhr

26.4
(±4.7)

20.6
(±4.8)

26.2
(±4.9)

24.2
(±2.7)

29.1
(±5.1)

26.4
(±3.7)

26.4
(±3.7)

82 V/FL

182
(±38)

198
(±52)

176
(±40)

168
(±24)

201
(±44)

183
(±37)

183
(±37)

0.250

0.250

0.250

0.250

0.250

0.250

0.250

1.35

1.35

1.35

1.35

1.35

1.35

1.35

85 Itra

14.8
(±4.5)

NA

14.l
(±4.6)

13.8
(±3.7)

17.1
(±4.6)

14.8
(±4.3)

14.8
(±4.3)

86CF

25.9
(±8.2)

25.9
(±11.8)

NA

23.2
(±6.1)

31.1
(±10.2)

25.8
(±6.9)

25.9
(±6.9)

87 Form

1.14
(±0.179)

1.22
(±0.22)

1.11
(±0.187)

NA

88TPT

0.355
(±0.106)

0.434
(±0.118)

0.423
(±0.073)

0.34
(±0.09)

NA

89 Sex

7.6e-007
(±4.80))1(

6.80
(±6.9))1(

2.02
(±5.45))1(

3.3e-011
(±4.68))1(

5.3e-005
(±5.43))1(

NA

NI

%CV

18.6%

19.2%

28.5%

21.6%

19.5%

18.5%

18.6%

Residual
Error

49.6%

56.1%

49.7%

48.9%

52.1%

49.6%

49.6%

ka83
Sand h-1
ka84
Neo h-1

No Form NoTPT

No Sex

Final

-1269.26 -1369.92 -1369.93

1.18
1.14
1.14
(±0.227) (±0.179) (±0.179)
0.355
0.355
(±0.106) (±0.106)

)!(denotes null value in the estimates; MOF= Minimum value of Objective function;
Form= Formulation; Neo=Neoral; Sand= Sandimmune; TPT =Time post transplant;
TVCL=THETA( 1)-THET A(5)*ITRA+ THETA(6)*CF
CL=TVCL *EXP(ET A( 1))
TVV=THET A(2)
V=TVV
IF (TPT .LE.4) TVFl = 1*DOSE+THET A(7)*( 1-DOSE)-THET A(8)!fPT
Fl= TVFl
IF (TPT.GT.4) TVFl=l *DOSE+THETA(7)*(1-DOSE)
Fl=TVFl
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Table 2.4. Comparison of Estimates for Base and Final Model

Base Model
Parameter
(units)
81CL/F1Jhr

Final Model

Parameter
Interpatient
Estimates (95 %
Variability
Cl)
CV% (95% Cl)
23.1(19.8 - 26.4) 32.l (24.2 -38.3)

Parameter
Estimates (95 %
Cl)
26.4 (22.7 - 30.l)

Interpatient
Variability CV
% (95% CI)
18.5 (13.6 - 23.4)

202 (159 - 245)

NA

183(146-220)

NA

83 I 84 (ka) h-1
Sandimmune
Neoral
85 Itra

0.25 Fixed
1.35 Fixed
NA

NA
NA
NA

0.25 Fixed
1.35 Fixed
14.8(10.5-19.l)

NA
NA
NA

86CF

NA

NA

25.9(19 - 32.8)

NA

87F

NA

NA

1.14 (0.96 - 1.32)

NA

88TPT

NA

NA

0.355 (0.248-0.462)

NA

NA

49.6 (45.6-53.2)

NA

82 (V/F) L

Residual error 60. l (50.9 -68.2)
CV

Abbreviations: CL/F =clearance; V/F =volume of distribution; ka =absorption rate constant;
ltra= ltraconazole; CF=Cystic Fibrosis; F=Bioavailability; NA= not applicable
TVCL=THETA(l)-THET A(5)*1TRA+ THET A(6)*CF; CL=TV CL *EXP(ETA( I))
TVV=THET A(2); V= TVV
K=ClJV
IF (DOSE.EQ.l) TVKA=THETA(3)
KA=TVKA
IF (DOSE.EQ.O) TVKA=THETA(4)
KA=TVKA
S2=V
IF (TPT.LE.4) TVF l=l *DOSE+THET A(7)*(1-DOSE)-THET A(8)/TPT
Fl=TVFl
IF (TPT.GT.4) TVFl=l *DOSE+THETA(7)*(1-DOSE)
Fl=TVFl
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Figure 2.1. Kernel Graph CLi/CLx Versus Weeks Post Transplant.
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Figure 2.2 (a): Base Model Observed Versus Model-Predicted Concentration
(mg/L)
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Figure. 2.2 (b): Weighted Residual Versus Model - Predicted Concentration
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Figure 2.3: Box Plot for Cystic Fibrosis as Covariate
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Figure 2.4: Box Plot for Formulation as Covariate.
Patients on Neoral =0 and patients on Sandimmune =1

50

:§' 40
:::i
_J

0

30

20

0
FORMULATION

65

Figure 2.5. Box Plot for ltraconazole as Covariate
Patients on itraconazole are marked 1, and patients not on itraconazole as 0.
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Figure 2.6 (a). Final Model Observed Versus Model - Predicted Concentration
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Figure 2.6 (b ).

Final Model Weighted Residual Versus Model - Predicted
Concentration
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APPENDIX A
Figure 3.1. NONMEM Control File for Base Model
$PROB RUN# (BASE RUN)
$INPUT C ID TIME AMT DV WT SS Dl=II TAD DOSE AGE SEX ITRA CF
TPT
$DATA 200.CSV IGNORE=C
$SUBROUTINES ADV AN2 TRANS2
$PK
TVCL=THETA (1)
CL=TVCL*EXP (ETA (1))
TVV=THETA (2)
V=TVV
K=CUV
IF (DOSE.EQ.l) TVKA=THETA (3)
KA=TVKA
IF (DOSE.EQ.O) TVKA=THETA (4)
KA=TVKA
S2=V
$ERROR
Y=F*(l+ERR (1))
$THETA
(0,105,500) (1,1000,5000) (0.25 FIXED) (1.35 FIXED)
$OMEGA
0.5; [P] INTERIND VAR IN CL
$SIGMA
0.3; [P] PROPORTIONAL COMPONENT
$EST MAXEY AL=5000 PRINT=5 POSTHOC MSF=Base.MSF
$COVARIANCE
$TABLE ID TIME DOSE TAD IPRED CL V NOPRINT ONEHEADER
FILE=Base.TAB
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Figure 3.2. NONMEM Control File for Time Post Transplant
$PROB RUN# TPT COY
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF
TPT
$DATA 200.CSV IGNORE=C
$SUBROUTINES ADV AN2 TRANS2
$PK
TVCL=THETA (1)
CL=TVCL*EXP (ETA (1))
TVV=THETA (2)
V=TVV
K=CUV
IF (DOSE.EQ.1) TVKA=THETA (3)
KA=TVKA
IF (DOSE.EQ.O) TVKA=THETA (4)
KA=TVKA
S2=V
IF (TPT.LE.4) TVFl=l-THETA (5)/TPT
Fl=TVFl
IF (TPT.GT.4) TVFl=l
Fl=TVFl
$ERROR
Y=F*(l+ERR (1))
$THETA
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED) (0,0.007,0.6)
$OMEGA
0.5; [P] INTERIND VAR IN CL
$SIGMA
0.3; [P] PROPORTIONAL COMPONENT
$EST MAXEY AL=5000 PRINT=5 POSTHOC
$COY ARIANCE
$TABLE ID TIME DOSE TAD IPRED CL TPT NO PRINT ONEHEADER
FILE=TPT.T AB
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Figure 3.3. NONMEM Control File for Itraconazole as Covariate
$PROB RUN# ltra cov
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF
TPT
$DATA 200.CSV IGNORE=C
$SUBROUTINES ADV AN2 TRANS2
$PK
TVCL=THETA (1)-THETA (5)*ITRA
CL=TV CL*EXP (ETA (1))
TVV=THETA (2)
V=TVV
K=CUV
IF (DOSE.EQ.l) TVKA=THETA (3)
KA=TVKA
IF (DOSE.EQ.O) TVKA=THETA (4)
KA=TVKA
S2=V
$ERROR
Y=F*(l+ERR (1))
$THETA
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED) (0, 10, 25)
$OMEGA
0.5; [P] INTERIND VAR IN CL
$SIGMA
0.3; [P] PROPORTIONAL COMPONENT
$EST MAXEY AL=5000 PRINT=5 POSTHOC
$COVARIANCE
$TABLE ID TIME DOSE TAD IPRED CL ITRA NOPRINT ONEHEADER
FILE=ltra.T AB
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Figure 3.4. NONMEM Control File for Formulation as Covariate.
$PROB RUN# FORMULATION
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF
TPT
$DATA 200.CSV IGNORE=C
$SUBROUTINES ADV AN2 TRANS2
$PK
TVCL=THETA (1)
CL=TVCL*EXP (ETA (1))
TVV=THETA (2)
V=TVV
K=CUV
IF (DOSE.EQ.l) TVKA=THETA (3)
KA=TVKA
IF (DOSE.EQ.0) TVKA=THETA (4)
KA=TVKA
S2=V
Fl=l *DOSE+THETA (5)*(1-DOSE)
$ERROR
Y=F*(l+ERR (1))
$THETA
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED)(0,1,5)
$OMEGA
0.5; [P] INTERIND VAR IN CL
$SIGMA
0.3; [P] PROPORTIONAL COMPONENT
$EST MAXEY AL=5000 PRINT=5 POSTHOC
$COVARIANCE
$TABLE ID TIME DOSE TAD IPRED CL NOPRINT ONEHEADER
FILE=formulation.TAB
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Figure 3.5. NONMEM Control File for Cystic Fibrosis as Covariate
$PROB RUN# CF COV
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF
TPT
$DATA 200.CSV IGNORE=C
$SUBROUTINES ADV AN2 TRANS2
$PK
TVCL=THETA (1) +THETA (5)*CF
CL=TVCL*EXP (ETA (1))
TVV=THETA (2)
V=TVV
K=CUV
IF (DOSE.EQ.1) TVKA=THETA (3)
KA=TVKA
IF (DOSE.EQ.O) TVKA=THETA (4)
KA=TVKA
S2=V
$ERROR
Y=F*(l+ERR (1))
$THETA
(0,105,500) (1, 1000, 5000) (0.25 FIXED) (1.35 FIXED) (0, 35)
$OMEGA
0.5; [P] INTERIND VAR IN CL
$SIGMA
0.3; [P] PROPORTIONAL COMPONENT
$EST MAXEY AL=5000 PRINT=5 POSTHOC
$COVARIANCE
$TABLE ID TIME TAD IPRED DOSE CL CF NOPRINT ONEHEADER
FILE=CF.TAB
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Figure 3.6. NONMEM Control File for Final Model
$PROB RUN# Final Model
$INPUT C ID TIME AMT DV WT SS DI=II TAD DOSE AGE SEX ITRA CF
TPT
$DATA 200.CSV IGNORE=C
$SUBROUTINES ADV AN2 TRANS2
$PK
TVCL=THETA (1)-THETA (5)*1TRA+THETA (6)*CF
CL=TVCL*EXP (ETA (1))
TVV=THETA (2)
V=TVV
K=CUV
IF (DOSE.EQ.l) TVKA=THETA (3)
KA=TVKA
IF (DOSE.EQ.O) TVKA=THETA (4)
KA=TVKA
S2=V
IF (TPT.LE.4) TVFl=l *DOSE+THETA (7)*(1-DOSE)-THETA (8)trPT
Fl=TVFl
IF (TPT.GT.4) TVFl=l *DOSE+THETA (7)*(1-DOSE)
Fl=TVFl
$ERROR
Y=F*(l+ERR (1))
$THETA
(0,105 ,500) (1,1000,5000)(0.25 FIXED) (1.35 FIXED)(O,O.l,20)(0,5,35)(0.5,2,5)
(0, 0.007' 0.6)
$OMEGA
0.5; [P] INTERIND VAR IN CL
$SIGMA
0.3; [P] PROPORTIONAL COMPONENT
$EST MAXEY AL=5000 PRINT=5 POSTHOC
$COVARIANCE
$TABLE ID TIME DOSE TAD CL ITRA CF TPT NOPRINT ONEHEADER
FILE=Final. TAB
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Figure 4.1. Results From the Analysis
a. Base Model

MINIMUM VALUE OF OBJECTIVE FUNCTION:

-456.975

95% CONFIDENCE INTERVAL
FINAL
ESTIMATE
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2
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3
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4
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10.7%

21.9%

14.8%
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INTERINDIVIDUAL
VARIABILITY
32.1%
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0.256
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VARIABILITY
0.466 CV=
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%RSE is percent relative standard error (100% x SE/EST)
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b. Cystic Fibrosis
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c. ltraconazale
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d. Gender

MINIMUM VALUE OF OBJECTIVE FUNCTION:
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e. Formulation
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f. Time Post Transplant
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g. Final Model
MINIMUM VALUE OF OBJECTIVE FUNCTION:
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